D. Boral Capital Begins Coverage on Compass Therapeutics (NASDAQ:CMPX)

D. Boral Capital initiated coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a research note issued to investors on Monday,Benzinga reports. The brokerage set a “buy” rating and a $32.00 price target on the stock.

Other analysts have also issued research reports about the company. Leerink Partnrs lowered Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 15th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Monday, November 11th. LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective for the company in a research report on Monday, September 16th. Finally, Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $5.00 to $4.00 in a research report on Friday, November 15th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.80.

Compass Therapeutics Trading Up 0.7 %

Shares of CMPX opened at $1.38 on Monday. The company’s fifty day simple moving average is $1.65 and its 200 day simple moving average is $1.41. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.34. The company has a market cap of $189.87 million, a price-to-earnings ratio of -3.73 and a beta of 0.89.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.03. As a group, research analysts forecast that Compass Therapeutics will post -0.35 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Barclays PLC grew its stake in shares of Compass Therapeutics by 195.4% in the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after acquiring an additional 112,614 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Compass Therapeutics by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock valued at $4,251,000 after purchasing an additional 19,095 shares during the period. XTX Topco Ltd bought a new stake in Compass Therapeutics in the 3rd quarter valued at about $37,000. The Manufacturers Life Insurance Company acquired a new position in shares of Compass Therapeutics during the 3rd quarter worth approximately $79,000. Finally, Intech Investment Management LLC bought a new position in shares of Compass Therapeutics during the third quarter worth approximately $30,000. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.